Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), headquartered in Irvine, California, operates as a clinical-stage biotechnology company targeting the CD40 Ligand (CD40L) pathway to develop immune-modulating therapies. The company's lead candidate, tegoprubart (formerly AT-1501), is an IgG1 anti-CD40L antibody designed to prevent organ or cell transplant rejection and explore applications in autoimmune and neurodegenerative conditions. As of February 27, 2026, ELDN closed at $2.62 per share, reflecting an 8.26 percent daily increase with a market capitalization of approximately $208.6 million. The 52-week range spans $1.35 to $4.60. In January 2026, Eledon raised $57.5 million through an underwritten public offering, extending cash runway into Q2 2027.
Company Background and Rebranding
Eledon Pharmaceuticals, formerly Novus Therapeutics, Inc., changed its name in January 2021 following the acquisition of Anelixis Therapeutics and its anti-CD40L assets. The focus shifted to immunology, specifically the CD40/CD40L costimulatory pathway central to adaptive and innate immune responses. The mission centers on “One Transplant for Life,” aiming to extend organ longevity and improve recipient quality of life by reducing rejection risks without traditional calcineurin inhibitor toxicities.
Lead Candidate: Tegoprubart (Anti-CD40L Antibody)
Tegoprubart binds with high affinity to CD40 Ligand (CD154), blocking interactions that drive immune activation and rejection. Key attributes include its design as a high-affinity IgG1 monoclonal antibody that avoids thromboembolic risks associated with earlier anti-CD40L therapies through Fc-engineered design. It targets prevention of rejection in allogeneic and xenogeneic transplants and is being explored in kidney allograft, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Preclinical collaboration with eGenesis uses tegoprubart in xenotransplantation regimens.
Clinical Pipeline and Key Trial Data
Eledon's programs center on transplant indications with tegoprubart as core immunosuppression.
In kidney transplantation, Phase 1b open-label trial long-term extension 24-month data from eight patients presented January 23, 2026, showed preserved kidney function (mean eGFR increase) and continued safety and tolerability. The Phase 2 BESTOW trial (NCT05983770) delivered topline results in November 2025 showing tegoprubart maintained excellent kidney function with reduced new-onset diabetes, tremor, and delayed graft function compared to tacrolimus. Advancement to Phase 3 is planned post-regulatory discussions.
In islet cell transplantation in Type 1 diabetes, an investigator-sponsored Phase 1/II trial (NCT06305286) at University of Chicago showed preliminary data from the first six patients (November 2025) with insulin-free management, sustained HbA1c control without calcineurin inhibitors. The trial was extended to 12 subjects with an additional study funded by Breakthrough T1D for patients with chronic kidney disease.
Recent Corporate and Financial Updates
On January 8, 2026, Eledon summarized 2025 milestones and 2026 outlook, noting the $57.5 million offering completion. On February 5, 2026, the company announced a fireside chat at the Guggenheim Biotech Summit scheduled for February 12, 2026. Analyst consensus lists Strong Buy from limited coverage. Media coverage includes patient stories in islet trials, such as an Arkansas participant achieving insulin independence.
When an anti-CD40L antibody keeps transplanted islets producing insulin without tacrolimus side effects in early patients, the path to one transplant for life runs through fewer daily injections.